How do GLP-1 receptor agonists differ from DPP-4 inhibitors in terms of mechanism and clinical effects?

• A. GLP-1 receptor agonists are incretin mimetics that enhance insulin secretion and slow gastric emptying, often with weight loss and greater HbA1c reductions; DPP-4 inhibitors increase endogenous incretin by inhibiting breakdown, with modest HbA1c reductions and weight neutrality.
• B. GLP-1 receptor agonists inhibit DPP-4; DPP-4 inhibitors stimulate insulin release directly from beta cells.
• C. GLP-1 receptor agonists cause weight gain; DPP-4 inhibitors cause significant weight loss.
• D. GLP-1 receptor agonists have no effect on gastric emptying; DPP-4 inhibitors dramatically increase insulin production in the liver.

Answer: (A)

GLP-1 receptor agonists act as incretin mimetics that directly stimulate GLP-1 receptors. This drives a glucose-dependent increase in insulin secretion, suppresses glucagon after meals, and slows gastric emptying. The slowing of gastric emptying helps blunt postprandial glucose spikes and often contributes to weight loss, along with generally larger reductions in HbA1c compared with other classes. Because they mimic the incretin effect more robustly and for a longer duration, they tend to produce these stronger glycemic improvements and weight loss.

DPP-4 inhibitors work by blocking the enzyme that breaks down endogenous incretin hormones like GLP-1 and GIP. This raises levels of incretins rather than activating receptors directly. The result is a more modest enhancement of insulin secretion and glucagon suppression, with smaller HbA1c reductions and usually weight neutrality, since there isn’t the same direct impact on gastric emptying or appetite.

So the key difference is direct receptor activation and gastric emptying modification with GLP-1 receptor agonists (leading to greater HbA1c reduction and weight loss), versus indirect incretin preservation with DPP-4 inhibitors (leading to modest HbA1c improvement and weight neutrality).